Evidence map›Paper›PMID 18053220›Full record

ArticleRespiratory research2007

Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma.

Venkata R Narala, Rajesh Ranga, Monica R Smith, Aaron A Berlin, Theodore J Standiford, Nicholas W Lukacs, Raju C Reddy

Open access · goldAbstract readComparative Study
In one paragraph

Article in Respiratory research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Pioglitazone prevents obesity-related airway hyperreactivity and neuronal MAmerican journal of physiology. Lung cellular and molecular physiology · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity.American journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014
    Article
  19. Article
  20. Cockroach allergens induce biphasic asthma-like pulmonary inflammation in outbred mice.The Journal of asthma : official journal of the Association for the Care of Asthma · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Venkata R NaralaDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109-2200, USA. narala@umich.edu
Rajesh Ranga
Monica R Smith
Aaron A Berlin
Theodore J Standiford
Nicholas W Lukacs
Raju C Reddy
University of Michigan–Ann Arbor · USMichigan Medicine · US

Funding

PPARGamma in Sepsis-Induced ImmunosuppressionK08HL070068 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, RAJU C · 2002 to 2006
$663k
NHLBI NIH HHS HL070068NHLBI NIH HHS K08 HL070068
6 · The paper itself

Abstract

backgroundWhile glucocorticoids are currently the most effective therapy for asthma, associated side effects limit enthusiasm for their use. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activators include the synthetic thiazolidinediones (TZDs) which exhibit anti-inflammatory effects that suggest usefulness in diseases such as asthma. How the ability of TZDs to modulate the asthmatic response compares to that of glucocorticoids remains unclear, however, because these two nuclear receptor agonists have never been studied concurrently. Additionally, effects of PPAR-gamma agonists have never been examined in a model involving an allergen commonly associated with human asthma.

methodsWe compared the effectiveness of the PPAR-gamma agonist pioglitazone (PIO) to the established effectiveness of a glucocorticoid receptor agonist, dexamethasone (DEX), in a murine model of asthma induced by cockroach allergen (CRA). After sensitization to CRA and airway localization by intranasal instillation of the allergen, Balb/c mice were challenged twice at 48-h intervals with intratracheal CRA. Either PIO (25 mg/kg/d), DEX (1 mg/kg/d), or vehicle was administered throughout the period of airway CRA exposure.

resultsPIO and DEX demonstrated similar abilities to reduce airway hyperresponsiveness, pulmonary recruitment of inflammatory cells, serum IgE, and lung levels of IL-4, IL-5, TNF-alpha, TGF-beta, RANTES, eotaxin, MIP3-alpha, Gob-5, and Muc5-ac. Likewise, intratracheal administration of an adenovirus containing a constitutively active PPAR-gamma expression construct blocked CRA induction of Gob-5 and Muc5-ac.

conclusionGiven the potent effectiveness shown by PIO, we conclude that PPAR-gamma agonists deserve investigation as potential therapies for human asthma.

Indexed as

Disease Models, AnimalAllergensAnimalsAntigens, PlantAsthmaDexamethasoneFemaleMiceMice, Inbred BALB CPioglitazoneThiazolidinedionesallergen CRa, cockroachAllergensAntigens, PlantDexamethasonePioglitazoneThiazolidinediones

Identifiers

PMID18053220
PMCPMC2231357
OpenAlexW2084319738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.